Lung Adenocarcinoma

Spontaneous pneumothorax in high-risk elderly smokers may mask occult lung cancer, even with negative HRCT findings. Clinicians should maintain high suspicion and routinely utilize intraoperative frozen section analysis for resected bullae to prevent delayed diagnosis and ensure timely oncological management.

Initial therapy with 'pemetrexed + carboplatin + tislelizumab' was administered...The RA flare was managed with methylprednisolone 1 mg/kg/day followed by a slow prednisone taper and sulfasalazine. Treatment was switched to 'pemetrexed + carboplatin + bevacizumab'...It may create a potential opportunity for conversion surgery in well-responding patients, enabling long-term disease control. This case underscores the critical importance of highly individualized, multidisciplinary treatment decision-making.

In summary, the Hippo pathway-associated lncRNA signature provides a readout for oncogenic YAP activity across cancers, suggesting its potential as a pan-cancer biomarker. Our results highlight oncogene-specific lncRNA signatures as valuable tools for diagnostics, therapy selection, and treatment monitoring.

RCAN-driven SR reconstruction effectively addresses CT resolution limitations, capturing fine-grained radiogenomic signatures critical for molecular phenotyping. This high-fidelity framework offers a robust, non-invasive decision-support tool for personalized precision oncology in LUAD.

A 19-gene signature derived from the virtual tumor framework stratified patients most likely to benefit from radiotherapy, which was validated using TCGA data. These results demonstrate the utility of virtual tumors to predict effective therapeutic combinations and present a computational resource for large-scale screening of personalized therapies to guide clinical decision-making in NSCLC patients.

This study reveals for the first time a common mechanism by which the BD/HDAC2/H4K16ac/SMAD3 axis regulates malignant phenotypes in EGFR-TKI-resistant LUAD, offering a novel natural compound-based therapy.

Preoperative identification of STAS remains a clinical challenge in stage IA lung adenocarcinoma. Our clinicoradiological model can simultaneously predict STAS and stratify recurrence risk. STAS-positive cases can be characterized by micropapillary/solid patterns and KRAS/ALK mutations. These findings may assist with surgical decision-making and facilitate tailored adjuvant therapy selection.

Therefore, this study clarifies how PFAS contribute to the development of LUAD and explores the molecular pathways involved, providing crucial insights into the toxicological effects of PFAS. Furthermore, it establishes a theoretical basis for devising preventive strategies and therapeutic approaches for pulmonary diseases related to PFAS exposure.

These findings identify the USP20-SQSTM1-autophagy axis as a key mechanism mediating ferroptosis resistance in LUAD and underscore USP20 as a promising therapeutic target.

This study elucidates the pivotal role of HDRGs in LUAD heterogeneity and malignant progression. The FOXA1-HDAC2 axis is identified as a novel regulatory pathway, providing a theoretical and experimental foundation for prognostic stratification and combination targeted therapy in LUAD.

Pharmacological prediction and experimental validation indicated that prostaglandin-endoperoxide synthase 2 (PTGS2) is a relevant target mediating the pharmacological effects of XHP: XHP downregulated the expression of PTGS2, while overexpression of PTGS2 attenuated the therapeutic effects of XHP. This study provides direct, single-cell-level spectroscopic evidence for the efficacy of XHP against lung adenocarcinoma and reveals a PTGS2-associated mechanism, offering new insights for the development of TCM-based therapies for lung adenocarcinoma.

Consistent with this, Cox regression analysis reveals that high expression of the TCA cycle enzyme OGDH is a top predictor of increased disease risk, while the glycolytic enzyme PGK1 is associated with a decreased risk. Our findings establish a direct link between transcriptional metabolic states and patient survival in LUAD, defining a framework for prognostic stratification and identifying subtype-specific metabolic vulnerabilities for therapeutic targeting.